Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Hypera Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Hypera hat ein durchschnittliches jährliches Gewinnwachstum von 9.4% verzeichnet, während die Branche Pharmaceuticals ein Gewinnwachstum gewachsen unter 10.9% jährlich einen Rückgang. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 21.6% pro Jahr. Hypera's return on equity is 14.5%, und die Nettomargen betragen 21.1%.

Wichtige Informationen

9.4%

Wachstumsrate der Gewinne

9.4%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	12.4%
Wachstumsrate der Einnahmen	21.6%
Eigenkapitalrendite	14.5%
Netto-Marge	21.1%
Nächste Ertragsaktualisierung	25 Jul 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Jul 19

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Jun 28

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Apr 14

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Mar 25

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Mar 04

Aufschlüsselung der Einnahmen und Ausgaben

Wie Hypera Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

BOVESPA:HYPE3 Einnahmen, Ausgaben und Erträge (BRL Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	8,043	1,701	2,511
31 Dec 23	7,915	1,649	2,521
30 Sep 23	8,189	1,773	2,531
30 Jun 23	8,086	1,742	2,492
31 Mar 23	7,751	1,694	2,375
31 Dec 22	7,546	1,705	2,299
30 Sep 22	7,051	1,640	2,121
30 Jun 22	6,648	1,636	2,017
31 Mar 22	6,260	1,660	1,955
31 Dec 21	5,937	1,618	1,895
30 Sep 21	5,446	1,577	1,872
30 Jun 21	4,902	1,462	1,756
31 Mar 21	4,445	1,382	1,626
31 Dec 20	4,089	1,322	1,564
30 Sep 20	3,883	1,243	1,538
30 Jun 20	3,803	1,165	1,605
31 Mar 20	3,726	1,106	1,635
31 Dec 19	3,295	1,189	1,611
30 Sep 19	3,294	1,252	1,558
30 Jun 19	3,233	1,225	1,508
31 Mar 19	3,180	1,164	1,469
31 Dec 18	3,724	1,135	1,481
30 Sep 18	3,789	1,288	1,508
30 Jun 18	3,716	1,251	1,477
31 Mar 18	3,613	1,200	1,430
31 Dec 17	3,500	1,111	1,410
30 Sep 17	3,291	819	1,397
30 Jun 17	3,226	795	1,380
31 Mar 17	3,216	743	1,394
31 Dec 16	3,228	647	1,372
30 Sep 16	3,202	557	1,360
30 Jun 16	3,129	432	1,339
31 Mar 16	3,046	349	1,323
31 Dec 15	2,957	345	1,307
30 Sep 15	1,589	263	774
30 Jun 15	2,039	326	944
31 Mar 15	2,447	360	1,095
31 Dec 14	2,768	338	1,245
30 Sep 14	4,498	400	1,913
30 Jun 14	4,423	357	1,863
31 Mar 14	4,359	249	1,851
31 Dec 13	4,259	259	1,804
30 Sep 13	4,167	332	1,727
30 Jun 13	4,047	324	1,681

Qualität der Erträge: HYPE3 hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: HYPE3Die aktuellen Gewinnspannen (21.1%) sind niedriger als im letzten Jahr (21.9%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: HYPE3In den letzten 5 Jahren sind die Gewinne von 9.4% jährlich gestiegen.

Beschleunigtes Wachstum: HYPE3Das Gewinnwachstum des Unternehmens im letzten Jahr (0.4%) liegt unter seinem 5-Jahres-Durchschnitt (9.4% pro Jahr).

Erträge im Vergleich zur Industrie: HYPE3 Das Gewinnwachstum im vergangenen Jahr (0.4%) übertraf nicht die Entwicklung der Branche Pharmaceuticals 7.3%.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: HYPE3Die Eigenkapitalrendite des Unternehmens (14.5%) wird als niedrig angesehen.

Hypera Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Hypera S.A. to Report Q3, 2024 Results on Nov 06, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings released: EPS: R$0.79 (vs R$0.72 in 2Q 2022)

First quarter 2023 earnings released

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Hypera S.A., Annual General Meeting, Apr 23, 2024

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Hypera (BVMF:HYPE3) A Risky Investment?

Hypera S.A. to Report Q3, 2024 Results on Nov 06, 2024

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued after recent price drop

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

New major risk - Financial position

Second quarter 2023 earnings released: EPS: R$0.79 (vs R$0.72 in 2Q 2022)

Is Hypera (BVMF:HYPE3) A Risky Investment?

First quarter 2023 earnings released

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Full year 2022 earnings released: EPS: R$2.69 (vs R$2.56 in FY 2021)

Hypera S.A. to Report Q4, 2022 Results on Feb 16, 2023

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Less than half of directors are independent

Third quarter 2022 earnings released

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Hypera Reportedly in Merger Talks with Grupo NC

Hypera S.A. to Report Q3, 2022 Results on Oct 28, 2022

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

First quarter 2022 earnings: Revenues in line with analyst expectations

Less than half of directors are independent

Hypera S.A. to Report Q1, 2022 Results on Apr 28, 2022

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Hypera S.A., Annual General Meeting, Apr 26, 2022

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Full year 2021 earnings: EPS exceeds analyst expectations

Hypera S.A. to Report Fiscal Year 2021 Results on Feb 24, 2022

Hypera S.A.(BOVESPA:HYPE3) dropped from Brazil Valor BM&FBOVESPA Index

Third quarter 2021 earnings released: EPS R$0.73 (vs R$0.56 in 3Q 2020)

Second quarter 2021 earnings released

First quarter 2021 earnings released: EPS R$0.48 (vs R$0.39 in 1Q 2020)

New 90-day low: R$30.52

Full year 2020 earnings released

Revenue and earnings beat expectations

Hypera S.A. to Report Q4, 2020 Results on Feb 26, 2021

New 90-day high: R$35.31

New 90-day high: R$32.34

Market bids up stock over the past week

New 90-day low: R$28.80

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings beat expectations

New 90-day low: R$30.22

Hypera S.A. (BOVESPA:HYPE3) completed the acquisition of Boehringer Ingelheim Buscopan brand and other assets from Boehringer Ingelheim International Gmbh, Boehringer Ingelheim do Brasil Química e Farmacêutica Ltda. and Boehringer Ingelheim Pharma GmbH & Co. KG.

New 90-day low - R$31.65

Bunge Alimentos S.A. acquired Food division of Hypera S.A. (BOVESPA:HYPE3) for BRL 180 million.

New 90-day high - R$36.25

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren